EyePoint Pharmaceuticals, Inc. - EYPT STOCK NEWS

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call and live webcast set for May 3, 2023, at 8:30 a.m. ET to report its first-quarter 2023 financial results and discuss recent corporate developments. The event will provide investors an opportunity to gain insights into the company's performance and strategic initiatives. EyePoint is focused on developing therapeutics for serious eye disorders, leveraging its proprietary Durasert technology for sustained drug delivery. Among its pipeline products is EYP-1901, currently in Phase 2 clinical trials, which targets intravitreal anti-VEGF treatment. EyePoint’s products, including YUTIQ, have previously gained FDA approval, showcasing its commitment to advancing eye care solutions.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced on April 17, 2023, the grant of non-statutory stock options for 13,000 shares to two new employees as part of an inducement package outside its 2016 Long-Term Incentive Plan. The options were granted on April 14, 2023, with an exercise price set at $4.33 per share, reflecting the stock’s closing price on that date. The options have a ten-year term and vest over four years, beginning with 25% vesting after one year, followed by monthly vesting thereafter. This move is in accordance with NASDAQ Listing Rule 5635(c)(4) and aims to enhance recruitment efforts by offering competitive compensation packages to new talent.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has successfully completed enrollment in its Phase 2 clinical trial, DAVIO 2, evaluating EYP-1901 for wet age-related macular degeneration (AMD). The trial exceeded its goal by enrolling 160 patients, with top-line data expected in Q4 2023. EYP-1901 aims to provide a six-month maintenance treatment option, addressing the significant treatment burden faced by wet AMD patients. The drug leverages EyePoint's Durasert technology for sustained delivery and has shown promising Phase 1 results, including a stable safety profile and visual acuity.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced positive scientific findings to be presented at the 2023 ARVO Annual Meeting. Key highlights include the neuroprotective effect of vorolanib in EYP-1901, demonstrating potential against retinal degeneration in a validated model. Additionally, findings from the CALM registry indicate effective control of inflammation in chronic posterior segment uveitis using YUTIQ. Presentations will cover preclinical data and clinical outcomes, including the Phase 1 DAVIO trial results showing a significant reduction in the need for anti-VEGF injections. The meeting takes place from April 23-27, 2023, in New Orleans.

EyePoint Pharmaceuticals announced its financial results for 2022, reporting a 13% increase in net product revenues to $39.9 million. The company has two Phase 2 clinical trials in progress for EYP-1901, targeting wet AMD and NPDR, with topline data expected by year-end 2023. In addition, operating expenses rose to $141 million, primarily due to a $20.7 million impairment charge from DEXYCU. EyePoint has $144.6 million in cash and investments, projected to fund operations into 2H 2024. The company also plans to disclose preclinical data at the upcoming 2023 ARVO Annual Meeting.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Mass., announced participation in two upcoming conferences. The Cowen 43rd Annual Healthcare Conference will feature a fireside chat on March 6, 2023, at 9:10 a.m. ET. The Guggenheim 4th Annual Healthy Altitudes Summit is scheduled for March 15, 2023, at 9:00 a.m. ET. Investors can access webcasts and archived replays via the company’s website. EyePoint specializes in developing therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery, including the investigational EYP-1901, currently in Phase 2 trials.

EyePoint Pharmaceuticals (NASDAQ: EYPT) and Rallybio Corporation have announced a research collaboration focused on the sustained delivery of Rallybio's complement component 5 (C5) inhibitor using EyePoint's Durasert technology. This partnership aims to develop a long-acting treatment for geographic atrophy, an advanced form of age-related macular degeneration leading to vision loss. EyePoint's Durasert technology offers a potential alternative to existing therapies, requiring less frequent injections. Approximately 1 million people in the U.S. are affected by geographic atrophy, highlighting the significant unmet medical need for effective treatments.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 2, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2022 financial results along with recent corporate developments.

The company's pipeline includes EYP-1901, an investigational treatment in Phase 2 clinical trials utilizing its Durasert® technology for sustained intraocular drug delivery. EyePoint has a track record with four FDA-approved products, including YUTIQ® for posterior segment uveitis, enhancing its position in the ophthalmic therapeutics market.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced on February 16, 2023, the granting of non-statutory stock options to two new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). A total of 6,000 stock options were issued at an exercise price of $3.70 per share, equal to the closing price on the grant date. The options will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments. The company is focused on therapeutics for serious eye disorders, leveraging its Durasert® technology.